Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice.

Cancer chemotherapy reports Pub Date : 1975-05-01
R H Liss, G L Neil
{"title":"Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice.","authors":"R H Liss,&nbsp;G L Neil","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The distribution of cyclocytidine and cytosine arabinoside has been studied in normal BDF mice and in mice bearing 6-day solid L1210 lymphocytic leukemia by whole-body radioautography, bioassay, and radiochemical techniques. Radioactivity was widely distributed throughout the tissues between 15 minutes and 12 hours after a single intravenous dose of either cyclocytidine-2-14C or cytosine arabinoside-2-14C. Whole-body radioautograms demonstrated that for most tissues, cytosine arabinoside-derived 14C was uniformly excreted by 48 hours; cyclocytidine-derived 14C, however, was localized in certain tissues as early as 15 minutes after drug administration and was retained in these sites for 48 hours. Depot loci of 14C included salivary and adrenal glands, fat, cardiac muscle, gastrointestinal tract, and L1210 tumor. The distribution and persistence of cyclocytidine-derived radioactivity is consistent with other reports of toxicity induced by the drug in these tissues. Radiochromatography and bioassay data from BDF mice dosed intraperitoneally with cyclocytidine demonstrated that 65%-95% of the 14C-radioactivity in a number of tissues was the parent compound itself. Thus, cyclocytidine contributed in large measur to the generation of the radioautograms. This study demonstrates that the retention of cyclocytidine in body tissues may serve to effect the sustained release of the deaminase-resistant chemotherapeutic drug from these depot sites and thus prolong cytotoxic levels of drug in tumor tissue.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 3","pages":"501-13"},"PeriodicalIF":0.0000,"publicationDate":"1975-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer chemotherapy reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The distribution of cyclocytidine and cytosine arabinoside has been studied in normal BDF mice and in mice bearing 6-day solid L1210 lymphocytic leukemia by whole-body radioautography, bioassay, and radiochemical techniques. Radioactivity was widely distributed throughout the tissues between 15 minutes and 12 hours after a single intravenous dose of either cyclocytidine-2-14C or cytosine arabinoside-2-14C. Whole-body radioautograms demonstrated that for most tissues, cytosine arabinoside-derived 14C was uniformly excreted by 48 hours; cyclocytidine-derived 14C, however, was localized in certain tissues as early as 15 minutes after drug administration and was retained in these sites for 48 hours. Depot loci of 14C included salivary and adrenal glands, fat, cardiac muscle, gastrointestinal tract, and L1210 tumor. The distribution and persistence of cyclocytidine-derived radioactivity is consistent with other reports of toxicity induced by the drug in these tissues. Radiochromatography and bioassay data from BDF mice dosed intraperitoneally with cyclocytidine demonstrated that 65%-95% of the 14C-radioactivity in a number of tissues was the parent compound itself. Thus, cyclocytidine contributed in large measur to the generation of the radioautograms. This study demonstrates that the retention of cyclocytidine in body tissues may serve to effect the sustained release of the deaminase-resistant chemotherapeutic drug from these depot sites and thus prolong cytotoxic levels of drug in tumor tissue.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小鼠环胞苷(NSC-145668)和阿拉伯糖胞苷(NSC-63878)的比较研究。
通过全身放射自显影、生物测定和放射化学技术,研究了正常BDF小鼠和患有6天固体L1210淋巴细胞白血病的小鼠体内环胞苷和阿拉伯糖胞嘧啶的分布。在单次静脉注射环胞苷-2- 14c或阿拉伯糖胞嘧啶-2- 14c后15分钟至12小时内,放射性在组织中广泛分布。全身放射自图显示,对于大多数组织,胞嘧啶阿拉伯糖衍生的14C在48小时内均匀排出;然而,环胞苷衍生的14C早在给药后15分钟就定位于某些组织,并在这些部位保留48小时。14C的位点包括唾液腺、肾上腺、脂肪、心肌、胃肠道和L1210肿瘤。环胞苷衍生的放射性的分布和持续与药物在这些组织中引起的毒性的其他报告一致。腹腔注射环胞苷的BDF小鼠的放射色谱和生物测定数据表明,在许多组织中65%-95%的14c放射性是母体化合物本身。因此,环胞苷在很大程度上促成了放射性自图的产生。本研究表明,环胞苷在体内组织中的保留可能有助于影响脱氨酶耐药化疗药物从这些储存位点的持续释放,从而延长药物在肿瘤组织中的细胞毒性水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PORFIROMYCIN. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease. Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma. Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)).
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1